The Potential CV Impact of Triglyceride Level Reduction

The EMPEROR-Preserved study investigated empagliflozin (Jardiance; Eli Lilly) for the treatment of heart failure with preserved ejection fraction.

Pharmacists can help patients through education, therapy, and lifestyle modifications.

The latest Heart Disease and Stroke Statistical Update highlighted pandemic-related trends that may impact cardiovascular disease mortality for years.

Investigators compared outcomes among patients with COVID-19 and hypertension through modifying blood pressure medication use.

An FDA panel voted to recommend the expanded use of sacubitril/valsartan (Entresto; Novartis).

This article reviews the evolving therapeutic landscape for lowering LDL-C and cardiovascular risk, with an emphasis on the role of omega-3 fatty acids.